Customization: | Available |
---|---|
Product Name: | Rebeprazole Sodium |
CAS: | 117976-90-6 |
Still deciding? Get samples of US$ 300/kg
Request Sample
|
Suppliers with verified business licenses
Audited by an independent third-party inspection agency
Product name | 99% Purity Rebeprazole Sodium API CAS117976-90-6 |
CAS NO. | CAS 117976-90-6 |
Appearance | White Powder |
Purity | 99% |
Application | Pharmaceutical raw materials |
Storage | Sealed in dry, Room Temperature |
Description:
Rebeprazole sodium was launched as Pariet in Japan, its first market, for the treatment of peptic ulcers including gastric and duodenal ulcers. From 4-chloro- 2,3-dimethylpyridine N-oxide, a six step synthesis allows access to the basic skeleton after successive condensations. Rabeprazole, a structural analog of Omeprazole, the first compound to have been marketed in this class up to now, is reported to be a more potent inhibitor of gastric H+/K+-adenosine triphosphate (ATPase) ; a common mechanism of action of this chemical class involves the conversion at low pH to a reactive sulphonamide that itself binds to cysteine residues located on the enzyme. Moreover, rabeprazole showed an antibacterial activity against Helicobacter Pylori, with a MIC90 of 1.56 μg/ml.
Rebeprazole sodium has a faster onset of action compared with omeprazole, but a shorter duration of action, being extensively and rapidly metabolized in several animal species. In clinical studies in patients with gastric ulcers, 10 and 20 mg rabeprazole sodium once-daily significantly inhibited basal and stimulated acid output. Rabeprazole is awaiting registration in the US for treatment of gastrooesophageal reflux disease (GORD) and other pathologic hypersecretory conditions including Zollinger-Ellison syndrome.
Uses:
It belongs to national second-class drug that can be used for the treatment of gastric ulcer. It can be used for the treatment of peptic ulcer, gastroesophageal reflux disease, zollinger-ellison syndrome and other diseases.